member
Sue LAM
Co-founder and COO, PenTide Therapeutics Limited
I am the co founder of PenTide Therapeutics Limited, a Hong Kong–based biotech company dedicated to advancing peptide therapeutics through innovative nasal delivery platforms, particularly for central nervous system and metabolic diseases. I received my Bachelor’s degree with first class honors and a PhD in Chemistry from HKUST, where I developed not only a strong scientific foundation, but also a deep appreciation for translating knowledge into impactful solutions. My journey to co founding PenTide was shaped by a simple but powerful question: how can we make advanced therapies more accessible and less burdensome for patients? I became increasingly aware of the limitations of conventional drug delivery—especially for brain-related conditions, where treatments are often invasive or inefficient. This challenge inspired me to explore intranasal delivery as a gentler, non invasive pathway to unlock better outcomes. PenTide was born from this vision—to bridge scientific innovation with real-world impact. Since inception, we have been building a proprietary platform and advancing a pipeline of peptide-based therapeutics. As a co founder, I am committed to leading both our science and strategy with purpose, bringing Hong Kong innovation to the global stage and, ultimately, improving patients’ lives.
Company Description
At PenTide Therapeutics Limited, we are transforming drug delivery through cutting-edge science. By harnessing advanced AI and innovative delivery systems, we rapidly discover and optimize life-changing peptide therapies. Our mission is to develop nasal peptide therapies that assist patients with conditions CNS and metabolic disease.
https://pentidetherapeutics.com